title: Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon α2b (IFNα2b) in cervical cancer.
abstract: Despite being a pleiotropic cytokine, the therapeutic potential of interferon α2b (IFNα2b) is debatable. Thus, the need for identifying predictive marker(s) for patients who are most likely to benefit from the treatment is pivotal for avoiding the exposure of nonresponsive patients to the toxicity of the treatment. To account for the attenuated efficacy of the drug, we have verified its dendritic cell (DC) maturating ability from monocytes of cervical cancer stage IIIB (CaCx-IIIB) patients. First, we evaluated the status of monocytes from CaCx-IIIB and healthy women by conducting flow cytometric studies of various activation markers and a cytokine analysis by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Immature DCs were then generated from these monocytes and matured with low-dose IFNα2b (1500 units/mL). A functional and phenotypic comparative analysis of these matured DCs was performed by flow cytometric, proliferative, cytotoxic, and enzyme-linked immunosorbent assays. Our study shows that monocytes isolated from CaCx-IIIB are impaired, and in vitro maturation with IFNα2b did not significantly improve the functional repertoire of DCs generated from these monocytes in comparison with healthy controls. This impairment of monocytes might be a plausible reason for the attenuated efficacy of this drug alone in treating CaCx-IIIB patients, and this imbalance of immune parameters associated with the stage of malignancy might be considered an effective marker to design a proper therapeutic regimen.
authors.affiliation: Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata 700026, India.
authors.forename: Soumyabrata
authors.initials: S
authors.lastname: Roy
authors.forename: Shyamal
authors.initials: S
authors.lastname: Goswami
authors.forename: Anamika
authors.initials: A
authors.lastname: Bose
authors.forename: Kuntal Kanti
authors.initials: KK
authors.lastname: Goswami
authors.forename: Koustav
authors.initials: K
authors.lastname: Sarkar
authors.forename: Krishnendu
authors.initials: K
authors.lastname: Chakraborty
authors.forename: Tathagata
authors.initials: T
authors.lastname: Chakraborty
authors.forename: Smarajit
authors.initials: S
authors.lastname: Pal
authors.forename: Atanu
authors.initials: A
authors.lastname: Haldar
authors.forename: Parthasarathi
authors.initials: P
authors.lastname: Basu
authors.forename: Jaydip
authors.initials: J
authors.lastname: Biswas
authors.forename: Rathindranath
authors.initials: R
authors.lastname: Baral
mesh_terms: D000328:Adult; D000368:Aged; D017951:Antigen Presentation / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016022:Case-Control Studies; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008213:Lymphocyte Activation; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D053633:Receptor, Interferon alpha-beta / Q000378:metabolism; D011994:Recombinant Proteins; D057170:Translational Research, Biomedical; D017211:Treatment Failure; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology
chemical_list: D016207:Cytokines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D053633:Receptor, Interferon alpha-beta